Hormonal
Obesity is associated with a significantly increased risk of kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers.
Maintaining a healthy weight is crucial for reducing your risk of kidney cancer. Research shows that for every 5 kg/m2 increase in BMI, your risk of kidney cancer increases by about 25%. This risk is driven by hormonal and inflammatory changes associated with excess body fat. Weight management is a key preventive strategy.
In a population-based study of 5.24 million individuals from the UK, a 5 kg/m2 higher BMI was associated with a 25% higher risk of kidney cancers, with 10% of all kidney cancers attributable to excess weight.
Why this rating
Based on large population-based studies, meta-analyses of 221 studies, and global burden of disease analyses.
Source
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Elena Zakharova · Urology & Nephrology Open Access Journal · 2017
DOI 10.15406/unoaj.2017.04.00127
More from this paper
- High body mass index (BMI ≥30 kg/m2) is a strong independent risk factor for the development and progression of Chronic Kidney Disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intra-glomerular pressure.Good
- Obesity increases the risk of nephrolithiasis (kidney stones) through multiple mechanisms including lower urine pH, increased urinary oxalate, uric acid, sodium, and phosphate excretion, and insulin resistance-induced acidic urine.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →